COMPANY PROFILE // THE 014 REPORT
Alector, Inc.
ALEC (Nasdaq) · Formerly: Alector LLC
Assembled from 3 government sources in 2.7 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberGLEIF: the direct parent is not reported; reporting exception filed with reason NON_PUBLIC.
- AmberLEI 549300Z8RQOIY1JMHC25 registration status is LAPSED (last update 2023-08-04): the legal-entity record has not been renewed.
✓ SEC filings✓ LEI✓ State registrationpossible match✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no website, no lobbying registration on record.
Alector, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), based in South San Francisco, CA; listed as ALEC (Nasdaq).[source] It reported revenue of $21.0 million for the fiscal year ended 2025-12-31.[source] It has filed 90 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-05.[source] Its largest institutional holders on 13F filings are TCG Crossover Management, LLC, Nantahala Capital Management, LLC, BlackRock, Inc. (as of 2026-06-30).[source] Seraphix flags 2 items from these records: LEI 549300Z8RQOIY1JMHC25 registration status is LAPSED (last update 2023-08-04); GLEIF.[source]
- red0
- amber2
- info0
- TCG Crossover Management, LLC$20.1M
- Nantahala Capital Management, LLC$17.4M
- BlackRock, Inc.$15.8M
- VANGUARD CAPITAL MANAGEMENT LLC$8.1M
- Kynam Capital Management, LP$7.7M
- Merck & Co., Inc.$7.1M
- Balyasny Asset Management L.P.$6.5M
- 683 Capital Management, LLC$6.4M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Berkley Neil Lindsay · CFO & Chief Business Officer (Officer) · latest Form 4 2026-03-13 · filing · LinkedIn search
- GRASSO MARC · Chief Financial Officer (Officer) · latest Form 4 2025-06-04 · filing · LinkedIn search
- Kenkare-Mitra Sara · President and Head of R&D (Officer) · latest Form 4 2025-12-03 · filing · LinkedIn search
- Rosenthal Arnon · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-13 · filing · LinkedIn search
- Wong-Sarad Grace · Principal Accounting Officer (Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- Altmeyer Mark · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- DESOUZA ERROL B · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- GAROFALO ELIZABETH A. · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- Hammond Paula · Director · latest Form 4 2025-08-27 · filing · LinkedIn search
- LAVIGNE LOUIS J JR · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- SCHELLER RICHARD H · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- Yaffe Kristine · Director · latest Form 4 2025-06-23 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Links
- Official website (Wikidata or the SEC record)
- Wikidata
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 24 CLEAR, 2 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001653087 | source |
| LEI | 549300Z8RQOIY1JMHC25 | source |
| EIN | 82-2933343 | source |
| California SOS entity | 0484116-01-001-0484116 | record |
| Connecticut business ID | 830581 | record |
| Business address (SEC) | 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2022-06-02 · in -1,632 days · LEI next renewal (549300Z8RQOIY1JMHC25)
- 2027-03-16 · in 116 days · Next 10-K due (period ended 2026-12-31; Accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 171 days · Next 10-Q due (period ended 2027-03-31; Accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Kyverna Therapeutics, Inc. · GRASSO MARC
- Unicycive Therapeutics, Inc. · Kenkare-Mitra Sara
- Royalty Pharma plc · DESOUZA ERROL B
- ACADIA PHARMACEUTICALS INC · GAROFALO ELIZABETH A.
- Xenon Pharmaceuticals Inc. · GAROFALO ELIZABETH A.
- Maze Therapeutics, Inc. · SCHELLER RICHARD H
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-16 filing 424B5 · SEC EDGAR
- 2026-10-16 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-10-16 filing FWP · SEC EDGAR
- 2026-10-14 officer change 8-K items 5.02 · SEC EDGAR
- 2026-10-05 filing 8-K items 1.01,2.02,7.01,8.01,9.01 · SEC EDGAR
- 2026-09-04 filing 144 · SEC EDGAR
- 2026-09-02 filing 144 · SEC EDGAR
- 2026-09-01 filing 144 · SEC EDGAR
- 2026-09-01 filing 144 · SEC EDGAR
- 2026-09-01 filing 144 · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-08 filing 8-K items 1.02 · SEC EDGAR
- 2026-06-17 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-03 filing 144 · SEC EDGAR
- 2026-06-01 filing 144 · SEC EDGAR
- 2026-06-01 filing 144 · SEC EDGAR
- 2026-06-01 filing 144 · SEC EDGAR
- 2026-05-07 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-05-07 filing 424B5 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-30 filing EFFECT · SEC EDGAR
- 2026-04-28 filing CORRESP · SEC EDGAR
- 2026-04-28 filing ARS · SEC EDGAR
- 2026-04-28 filing DEFA14A · SEC EDGAR
- 2026-04-28 filing Proxy statement · SEC EDGAR
- 2026-04-16 filing 144 · SEC EDGAR
164 earlier entries
- 2026-03-17 filing UPLOAD
- 2026-03-12 filing S-3
- 2026-03-10 filing 144
- 2026-03-03 filing 144
- 2026-02-27 filing 144
- 2026-02-27 filing 144
- 2026-02-27 filing 144
- 2026-02-26 filing 144
- 2026-02-25 filing S-8
- 2026-02-25 filing Annual report (10-K)
- 2026-02-25 filing 8-K items 2.02,9.01
- 2025-12-12 officer change 8-K items 5.02,9.01
- 2025-12-05 filing 144
- 2025-12-01 filing 144
- 2025-12-01 filing 144
- 2025-12-01 filing 144
- 2025-12-01 filing 144
- 2025-11-06 filing Quarterly report (10-Q)
- 2025-11-06 filing 8-K items 2.02,9.01
- 2025-10-21 officer change 8-K items 2.02,2.05,5.02,7.01,9.01
- 2025-08-29 filing 144
- 2025-08-29 filing 144
- 2025-08-29 filing 144
- 2025-08-29 filing 144
- 2025-08-26 filing 144
- 2025-08-08 filing 144
- 2025-08-07 filing Quarterly report (10-Q)
- 2025-08-07 filing 8-K items 2.02,9.01
- 2025-06-30 insider First Form 3/4/5 on record for Berkley Neil Lindsay (CFO & Chief Business Officer)
- 2025-06-30 insider First Form 3/4/5 on record for Wong-Sarad Grace (Principal Accounting Officer)
- 2025-06-13 officer change 8-K items 5.02,5.07,9.01
- 2025-06-12 insider First Form 3/4/5 on record for Altmeyer Mark (Director)
- 2025-06-12 insider First Form 3/4/5 on record for DESOUZA ERROL B (Director)
- 2025-06-12 insider First Form 3/4/5 on record for GAROFALO ELIZABETH A. (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Hammond Paula (Director)
- 2025-06-12 insider First Form 3/4/5 on record for LAVIGNE LOUIS J JR (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Yaffe Kristine (Director)
- 2025-06-04 insider First Form 3/4/5 on record for GRASSO MARC (Chief Financial Officer)
- 2025-06-04 insider First Form 3/4/5 on record for Kenkare-Mitra Sara (President and Head of R&D)
- 2025-06-04 insider First Form 3/4/5 on record for Rosenthal Arnon (Chief Executive Officer)
- 2025-05-30 filing 144
- 2025-05-30 filing 144
- 2025-05-30 filing 144
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-05-02 insider First Form 3/4/5 on record for SCHELLER RICHARD H (Director)
- 2025-04-25 filing ARS
- 2025-04-24 filing DEFA14A
- 2025-04-24 filing Proxy statement
- 2025-03-28 officer change 8-K items 5.02
- 2025-03-10 filing 8-K items 2.05
- 2025-02-28 filing 144
- 2025-02-28 filing 144
- 2025-02-28 filing 144
- 2025-02-28 filing 144
- 2025-02-26 filing S-8
- 2025-02-26 filing Annual report (10-K)
- 2025-02-26 filing 8-K items 2.02,9.01
- 2025-01-10 filing 8-K items 8.01
- 2024-11-29 filing 144
- 2024-11-29 filing 144
- 2024-11-29 filing 144
- 2024-11-29 filing 144
- 2024-11-25 filing 8-K items 2.05,7.01,9.01
- 2024-11-14 filing 8-K items 1.01,2.03,7.01,9.01
- 2024-11-06 filing Quarterly report (10-Q)
- 2024-11-06 filing 8-K items 2.02,9.01
- 2024-08-30 filing 144
- 2024-08-30 filing 144
- 2024-08-30 filing 144
- 2024-08-30 filing 144
- 2024-08-22 filing 144
- 2024-08-12 filing 144
- 2024-08-07 filing Quarterly report (10-Q)
- 2024-08-07 filing 8-K items 2.02,9.01
- 2024-06-12 filing 8-K items 5.07
- 2024-05-31 filing 144
- 2024-05-31 filing 144
- 2024-05-31 filing 144
- 2024-05-31 filing 144
- 2024-05-08 filing Quarterly report (10-Q)
- 2024-05-08 filing 8-K items 2.02,9.01
- 2024-04-25 filing ARS
- 2024-04-25 filing DEFA14A
- 2024-04-25 filing Proxy statement
- 2024-03-21 officer change 8-K items 5.02
- 2024-03-01 filing 144
- 2024-03-01 filing 144
- 2024-03-01 filing 144
- 2024-03-01 filing 144
- 2024-02-27 filing S-8
- 2024-02-27 filing Annual report (10-K)
- 2024-02-27 filing 8-K items 2.02,9.01
- 2024-01-19 filing 8-K items 1.01,8.01,9.01
- 2024-01-19 filing 424B5
- 2024-01-16 filing 8-K items 2.02
- 2024-01-16 filing 424B5
- 2023-12-01 filing 144
- 2023-12-01 filing 144
- 2023-12-01 filing 144
- 2023-12-01 filing 144
- 2023-11-07 filing 8-K items 1.01,9.01
- 2023-11-07 filing 424B5
- 2023-11-07 filing Quarterly report (10-Q)
- 2023-11-07 filing 8-K items 2.02,9.01
- 2023-09-11 filing 144
- 2023-09-11 filing 144
- 2023-09-11 filing 144
- 2023-09-01 filing 144
- 2023-09-01 filing 144
- 2023-09-01 filing 144
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-08-03 filing 8-K items 2.02,9.01
- 2023-06-15 filing 8-K items 5.03,5.07,9.01
- 2023-06-01 filing 144
- 2023-06-01 filing 144
- 2023-06-01 filing 144
- 2023-05-05 filing EFFECT
- 2023-05-04 filing Quarterly report (10-Q)
- 2023-05-04 filing 8-K items 2.02,9.01
- 2023-05-02 filing POS AM
- 2023-05-01 filing EFFECT
- 2023-04-27 filing CORRESP
- 2023-04-27 officer change 8-K items 5.02
- 2023-04-27 filing DEFA14A
- 2023-04-27 filing Proxy statement
- 2023-03-29 filing 8-K items 2.05
- 2023-03-13 filing 8-K items 7.01
- 2023-03-07 filing UPLOAD
- 2023-02-28 filing S-3
- 2023-02-28 filing S-8
- 2023-02-28 filing Annual report (10-K)
- 2023-02-28 filing 8-K items 2.02,9.01
- 2022-11-08 filing Quarterly report (10-Q)
- 2022-11-08 filing 8-K items 2.02,9.01
- 2022-10-06 officer change 8-K items 5.02
- 2022-09-26 filing S-8
- 2022-09-26 officer change 8-K items 5.02,9.01
- 2022-08-04 filing Quarterly report (10-Q)
- 2022-08-04 filing 8-K items 2.02,9.01
- 2022-07-07 filing 8-K items 8.01
- 2022-06-21 filing 8-K items 5.07
- 2022-05-27 filing DEFR14A
- 2022-05-05 filing Quarterly report (10-Q)
- 2022-05-05 filing 8-K items 2.02,9.01
- 2022-04-28 filing DEFA14A
- 2022-04-28 filing Proxy statement
- 2022-03-29 officer change 8-K items 5.02,9.01
- 2022-02-24 filing S-8
- 2022-02-24 filing Annual report (10-K)
- 2022-02-24 filing 8-K items 2.02,9.01
- 2022-02-07 officer change 8-K items 5.02,9.01
- 2022-01-03 officer change 8-K items 5.02,9.01
- 2022-01-03 filing S-8
- 2022-01-03 officer change 8-K items 5.02,9.01
- 2021-12-15 officer change 8-K items 5.02,9.01
- 2021-11-04 filing Quarterly report (10-Q)
- 2021-11-04 filing 8-K items 2.02,9.01
- 2021-09-28 officer change 8-K items 5.02,9.01
- 2021-09-08 officer change 8-K items 5.02
- 2021-09-07 officer change 8-K items 5.02,9.01
- 2021-08-03 filing Quarterly report (10-Q)
- 2021-08-03 filing 8-K items 2.02,9.01
- 2015-09-16 name change Name changed from Alector LLC
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-05 (within 30 days) 10-Q filed
- 2026-11-05 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-16 (older) 424B5 filed
- 2026-10-16 (older) 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-16 (older) FWP filed
- 2026-10-14 (older) 8-K filed: Item 5.02 officer or director change
- 2026-10-05 (older) 8-K filed: Item 1.01 material agreement; Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-06 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:ALEC The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
9 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1653087 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | ALEC / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300Z8RQOIY1JMHC25 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300Z8RQOIY1JMHC25) | GLEIF |
| EIN | 822933343 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001653087 | SEC EDGAR / IRS |
| CUSIP | 014442107 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001653087 | SEC EDGAR |
possible match: matched by name only, not merged (5)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110070420264 (ALECTOR LLC) | name-exact:legal-name: same registered legal name as 'Alector, Inc.' | EPA ECHO facilities |
| EPA FRS id | 110070591767 (ALECTOR LLC) | name-exact:legal-name: same registered legal name as 'Alector, Inc.' | EPA ECHO facilities |
| EPA FRS id | 110070420965 (ALECTOR LLC) | name-exact:legal-name: same registered legal name as 'Alector, Inc.' | EPA ECHO facilities |
| EPA FRS id | 110072040722 (ALECTOR, INC.) | name-exact:legal-name: same registered legal name as 'Alector, Inc.' | EPA ECHO facilities |
| EPA FRS id | 110070899151 (ALECTOR, LLC) | name-exact:legal-name: same registered legal name as 'Alector, Inc.' | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $21,045,000 | 2025-12-31 | 10-K, XBRL Revenues | as filed | 2026-11-21 00:31 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$142,929,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 00:31 UTC | Report an error |
| Total assets (at 2025-12-31) | $293,237,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 00:31 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $30,649,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 00:31 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $65,802,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 00:31 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-21 00:31 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-21 00:31 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-21 00:31 UTC | Report an error |
| Business address | 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080 | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-21 00:31 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-21 00:31 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$184,031,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 00:31 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $41,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 00:31 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $10,000,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-21 00:31 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $26,544,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 00:31 UTC | Report an error |
| Form D total offering amount (D filed 2015-09-16) | $32,275,003 | 2015-09-16 | D | as filed | 2026-11-21 00:31 UTC | Report an error |
| Form D total amount sold (D filed 2015-09-16) | $32,275,003 | 2015-09-16 | D | as filed | 2026-11-21 00:31 UTC | Report an error |
| Form D industry group | Biotechnology | 2015-09-16 | D | as filed | 2026-11-21 00:31 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2015-09-16 | D | as filed | 2026-11-21 00:31 UTC | Report an error |
| Form D date of first sale | 2015-09-01 | 2015-09-16 | D | as filed | 2026-11-21 00:31 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001193125-26-449871
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $162,866,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001193125-26-449871 | 2026-11-21 00:31 UTC | Report an error |
| Net income (loss) | $124,600,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001193125-26-449871 | 2026-11-21 00:31 UTC | Report an error |
| Cash and cash equivalents | $75,472,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001193125-26-449871 | 2026-11-21 00:31 UTC | Report an error |
| Contract liabilities, current | $0 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001193125-26-449871 | 2026-11-21 00:31 UTC | Report an error |
| Contract liabilities, noncurrent | $0 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001193125-26-449871 | 2026-11-21 00:31 UTC | Report an error |
| Debt due in the next 12 months (from an earlier report) | $365,914 | at 2025-12-31 | 10-K | 2026-02-25 | 0001193125-26-071593 | 2026-11-21 00:31 UTC | Report an error |
| Debt due in year 2 (from an earlier report) | $4,596,616 | at 2025-12-31 | 10-K | 2026-02-25 | 0001193125-26-071593 | 2026-11-21 00:31 UTC | Report an error |
| Debt due in year 3 (from an earlier report) | $5,037,470 | at 2025-12-31 | 10-K | 2026-02-25 | 0001193125-26-071593 | 2026-11-21 00:31 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-05 Filing 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-16 Filing 424B5 filed
- 2026-10-16 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-16 Filing FWP filed
- 2026-10-14 Filing 8-K filed: Item 5.02 officer or director change
- 2026-10-05 Filing 8-K filed: Item 1.01 material agreement; Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-08 Filing 8-K filed: Item 1.02 agreement terminated
- 2026-06-17 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-07 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-05-07 Filing 424B5 filed
- 2026-05-07 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-30 Filing EFFECT filed
- 2026-04-28 Filing CORRESP filed
- 2026-04-28 Filing ARS filed
- 2026-04-28 Filing DEFA14A filed
- 2026-04-28 Filing DEF 14A filed
- 2026-03-17 Filing UPLOAD filed
- 2026-03-12 Filing S-3 filed
- 2026-02-25 Filing S-8 filed
- 2026-02-25 Filing 10-K filed
- 2026-02-25 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-05 8-K Item 2.02, Results of Operations and Financial Condition
On November 5, 2026, Alector, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026. A press release announcing these results, which is attached hereto as Exhibit 99.1, is incorporated herein by reference. All of the information furnished in Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing. the 8-K · retrieved 2026-11-21 00:31 UTC - 2026-10-05 8-K Item 1.01, Entry Into a Material Definitive Agreement
License Agreement with Genentech On September 30, 2026, Alector, Inc. and Alector LLC (collectively, “Alector” or the “Company”) entered into a License Agreement (the “Genentech License Agreement”) with Genentech, Inc. (“Genentech”), pursuant to which Alector is granting Genentech exclusive worldwide rights to develop and commercialize Alector’s AL050 program, which is a brain penetrant engineered glucocerebrosidase (“GCase”) enzyme replacement therapy (the “GCase Candidates”). Under the Genentech License Agreement, Genentech will be responsible for development, regulatory, manufacturing, and commercialization of the GCase Candidates, and Alector will assign ownership of certain of its… the 8-K · retrieved 2026-11-21 00:31 UTC - 2026-10-05 8-K Item 2.02
Results of Operations and Financial Condition. On October 5, 2026, Alector announced its preliminary estimate of cash, cash equivalents, and marketable securities as of September 30, 2026, including after giving effect to the Genentech License Agreement and Spur Agreement. Based upon preliminary estimates and information available to the Company as of the date of this Form 8-K, cash, cash equivalents, and marketable securities totaled approximately $138.7 million as of September 30, 2026, and Alector would have approximately $223.7 million of cash, cash equivalents, and marketable securities as of September 30, 2026 after giving pro forma effect to the initial payments received under the… the 8-K · retrieved 2026-11-21 00:31 UTC - 2026-10-05 8-K Item 7.01
Regulation FD Disclosure. Alector has issued a press release which is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference. The information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing. the 8-K · retrieved 2026-11-21 00:31 UTC - 2026-10-05 8-K Item 8.01
Other Events. The disclosure referenced in Item 2.02 is incorporated by reference herein. the 8-K · retrieved 2026-11-21 00:31 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (5)
possible match: matched by name only, not merged (5)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchALECTOR LLC · exact legal name · sx:epa:110070420264 Compare
- possible matchALECTOR LLC · exact legal name · sx:epa:110070591767 Compare
- possible matchALECTOR LLC · exact legal name · sx:epa:110070420965 Compare
- possible matchALECTOR, INC. · exact legal name · sx:epa:110072040722 Compare
- possible matchALECTOR, LLC · exact legal name · sx:epa:110070899151 Compare
EPA RCRA hazardous waste (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchALECTOR LLC · exact legal name · sx:rcra:CAL000445096 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | $20,100,000 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
| 2 | Nantahala Capital Management, LLC | $17,358,798 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
| 3 | BlackRock, Inc. | $15,774,236 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $8,058,773 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
| 5 | Kynam Capital Management, LP | $7,655,073 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
| 6 | Merck & Co., Inc. | $7,126,896 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
| 7 | Balyasny Asset Management L.P. | $6,527,326 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
| 8 | 683 Capital Management, LLC | $6,432,000 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
| 9 | D. E. Shaw & Co., Inc. | $5,949,566 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
| 10 | ADAR1 Capital Management, LLC | $5,796,002 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:31 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- ALECTOR, INC. · LEI 549300Z8RQOIY1JMHC25 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
3 state and city records carry this company's exact name, from 3 sources. Possible matches only.
California business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAlector LLC · exact legal name · sx:cabiz:sf:0484116-01-001-0484116 Compare
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchALECTOR, INC. · exact legal name · sx:ctsos:830581 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAlector Inc. · exact legal name · sx:ctgov:hec6daa75a6321810 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1653087.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001653087. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.